Tracked deals
20
20 tracked deals across 2015-2026.
Public Company
Healthcare
Boston Scientific
Marlborough, Massachusetts, United States
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, it provides a broad range of high-performance solutions (devices and therapies) addressing unmet patient needs across cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.
- Focus Areas
- Cardiology, Cardiac rhythm management and electrophysiology, Interventional cardiology
- Website
- bostonscientific.com
Recent pace
4
4 tracked deals announced in the last 12 months.
Deal mix
Buyout
17 buyout · 1 addon · 1 divestiture
Boston Scientific Acquisition Volume by Year
Last 8 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
Showing the 12 most recent of 20 tracked deals for Boston Scientific.
-
May 18, 2026
- Buyer
- Boston Scientific Corporation
- Target
- MiRus LLC
- Industry
- Medical Devices
- Location
- Georgia, United States
- Type
- Growth capital
Boston Scientific Corporation invested $1.5 billion for an approximately 34% equity stake in privately held MiRus LLC. Under the investment agreement, Boston Scientific received an exclusive option to acquire MiRus’s SIEGEL balloon-expandable TAVR system business for up to $3 billion in additional cash payments, subject to clinical and regulatory milestones and closing conditions.
-
January 16, 2026
- Buyer
- Boston Scientific Corporation
- Target
- Penumbra, Inc.
- Industry
- Medical Devices
- Location
- California, United States
- Type
- Buyout
Boston Scientific signed a definitive agreement to acquire Penumbra, Inc. in a cash-and-stock transaction valued at about $14.5 billion on an enterprise value basis. The deal is designed to broaden Boston Scientific’s vascular and neurovascular portfolio, particularly in mechanical thrombectomy and adjacent neurovascular markets, with expected closing in 2026 subject to regulatory approvals and Penumbra shareholder approval.
-
January 12, 2026
- Buyer
- Boston Scientific
- Target
- Valencia Technologies
- Industry
- Medical Devices
- Location
- California, United States
- Type
- Buyout
Boston Scientific acquired Valencia Technologies to advance its urology and pelvic health portfolio, adding Valencia’s implantable tibial nerve stimulation technology. The deal is expected to close in the first half of 2026, with financial terms undisclosed.
-
October 17, 2025
- Buyer
- Boston Scientific Corporation
- Target
- Nalu Medical, Inc.
- Industry
- Healthcare Services
- Type
- Buyout
Boston Scientific entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on minimally invasive chronic pain neuromodulation. The deal includes an upfront cash payment of approximately $533 million for the remaining equity not already owned by Boston Scientific, with Boston Scientific expecting closing in the first half of 2026.
-
March 3, 2025
- Buyer
- Boston Scientific Corporation
- Target
- SoniVie Ltd.
- Industry
- Medical Devices
- Location
- Unknown
- Type
- Buyout
Boston Scientific Corporation has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company developing the TIVUS intravascular ultrasound system for renal denervation therapy for hypertension. The deal includes an upfront payment of approximately $360 million for the 90% stake Boston Scientific does not already own, plus up to $180 million contingent on achievement of a regulatory milestone.
-
January 8, 2025
- Buyer
- Boston Scientific Corporation
- Target
- Bolt Medical, Inc.
- Industry
- Medical Devices
- Location
- United States
- Type
- Buyout
Boston Scientific Corporation entered into a definitive agreement to acquire Bolt Medical, Inc., developer of an intravascular lithotripsy (IVL) laser-based platform for treating calcified coronary and peripheral artery disease. The deal includes an upfront payment of about $443 million for the 74% stake Boston Scientific does not already own, plus up to $221 million tied to regulatory milestones.
-
November 15, 2024
- Buyer
- Boston Scientific Corporation
- Target
- Axonics, Inc.
- Industry
- Medical Devices
- Location
- California, United States
- Type
- Buyout
Boston Scientific agreed to acquire Axonics, a medical technology company focused on urinary and bowel dysfunction, for $71 per share in cash, valuing the equity at approximately $3.7 billion. The boards approved the transaction, which was expected to close in the first half of 2024, and Boston Scientific later announced the acquisition closed on November 15, 2024.
-
November 4, 2024
- Buyer
- Boston Scientific Corporation
- Target
- Cortex, Inc.
- Seller
- Ajax Health
- Industry
- Medical Devices
- Location
- United States
- Type
- Buyout
Boston Scientific Corporation entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company, to complement its electrophysiology portfolio with Cortex’s diagnostic mapping technology for complex atrial fibrillation. Cortex’s OptiMap System uses a basket catheter and proprietary algorithm to identify atrial fibrillation triggers outside the pulmonary veins, which is intended to support more targeted ablation strategies.
-
- Buyer
- Boston Scientific Corporation
- Target
- Silk Road Medical, Inc.
- Seller
- Silk Road Medical stockholders
- Industry
- Medical Devices
- Location
- California, United States
- Type
- Buyout
Boston Scientific Corporation agreed to acquire Silk Road Medical, Inc. for $27.50 per share in an all-cash transaction valuing Silk Road's equity at approximately $1.26 billion. The acquisition brings Silk Road's TransCarotid Artery Revascularization (TCAR) platform into Boston Scientific's vascular portfolio to expand treatment options for carotid artery disease and strengthen the company's vascular technology offerings.
-
September 19, 2023
- Buyer
- Boston Scientific Corporation
- Target
- Relievant Medsystems, Inc.
- Industry
- Medical Devices
- Location
- Massachusetts, United States
- Type
- Buyout
Boston Scientific Corporation agreed to acquire Relievant Medsystems, Inc. to expand its neuromodulation portfolio and add the Intracept intraosseous nerve ablation system for vertebrogenic chronic low back pain. The deal includes an $850 million upfront cash payment plus contingent payments tied to sales, and is expected to close in the first half of 2024; Relievant was projected to generate more than $70 million in sales in 2023.
-
November 30, 2022
- Buyer
- Boston Scientific Corporation
- Target
- Apollo Endosurgery
- Industry
- Medical Devices
- Location
- United States
- Type
- Buyout
Boston Scientific Corporation has entered into a definitive agreement to acquire Apollo Endosurgery for $615 million in cash (approximately $10 per share). The deal expands Boston Scientific’s endoluminal surgery (ELS) capabilities and adds an adjacency into the endobariatric market.
-
August 15, 2022
- Buyer
- Boston Scientific Corporation
- Target
- Obsidio, Inc.
- Industry
- Medical Devices
- Location
- United States
- Type
- Buyout
Boston Scientific Corporation announced the acquisition of Obsidio, Inc., the developer of Gel Embolic Material (GEM) technology for peripheral embolization, strengthening Boston Scientific’s interventional oncology and embolization portfolio. The FDA-cleared GEM technology is a ready-to-use, semi-solid embolic intended to provide precise, controlled vessel occlusion; terms were not disclosed and the deal was described as immaterial to Boston Scientific’s 2022 EPS.
Related Acquisition Pages
Medical Devices Buyers & Acquisitions
18 tracked deals by Boston Scientific.
Healthcare Services Buyers & Acquisitions
2 tracked deals by Boston Scientific.
Acquisitions in California
6 tracked deals by Boston Scientific.
Acquisitions in Georgia
1 tracked deal by Boston Scientific.
Acquisitions in Massachusetts
1 tracked deal by Boston Scientific.
Selling a company? Get in front of buyers like Boston Scientific
Turn tracked acquisition activity into an outreach-ready buyer list.